DG

Daphne Gao

Associate Director Of Medical Writing & Medical Science at Zai Lab

Daphne (Chan) Gao has an extensive work experience in the field of medical writing and science. Daphne (Chan) is currently working as the Associate Director of Medical Writing & Medical Science at Zhenya Medicine, starting in April 2022. Prior to this, they were an Associate Director of Medical Writing at Brii Biosciences from April 2021 to April 2022. From October 2018 to April 2021, they served as the Medical Writing & Communication Lead at Ideogen. Daphne (Chan) also worked as a Senior Medical Science Liaison at The Janssen Pharmaceutical Companies of Johnson & Johnson from September 2015 to August 2017. Before that, they were a Technical Advisor at Medistem Inc, where they provided interpretation of complex biological matters and drafted scientific documents. Daphne (Chan) started their career as a Research Assistant at McMaster University, where they investigated the impact of cAMP receptor protein and studied the function of the ATPase VirB4 in various research projects.

Daphne (Chan) Gao completed their education with a B.Sc. in Biochemistry and Molecular Biology from Nankai University in 2003. Daphne (Chan) then pursued an M.Sc. in Biology at McMaster University from 2004 to 2006. Continuing their academic journey, they obtained a Ph.D. in Molecular Microbiology from McMaster University, completing their studies in 2012.

Links

Previous companies


Org chart

No direct reports

Teams


Offices

This person is not in any offices


Zai Lab

5 followers

Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.


Industries

Headquarters

Shanghai, China

Employees

201-500

Links